Astrana Health Unveils Financial Slides for Conference
These 4 Measures Indicate That Astrana Health (NASDAQ:ASTH) Is Using Debt Reasonably Well
Astrana Health's Earnings Growth Potential Through RAF Score Enhancement: A Buy Rating Analysis
Analysts Conflicted on These Healthcare Names: Quest Diagnostics (DGX), Astrana Health (ASTH) and Dexcom (DXCM)
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
Astrana Health (NASDAQ:ASTH) Could Be Struggling To Allocate Capital
Astrana Health's (NASDAQ:ASTH) Strong Earnings Are Of Good Quality
Baird Maintains Astrana Health(ASTH.US) With Buy Rating, Raises Target Price to $67
Baird analyst Michael Ha maintains $Astrana Health(ASTH.US)$ with a buy rating, and adjusts the target price from $54 to $67.According to TipRanks data, the analyst has a success rate of 65.4% and a
Baird Maintains Outperform on Astrana Health, Raises Price Target to $67
Astrana Health and Awell Forge Partnership to Bring CareOps to Value-Based Healthcare
Astrana Health | 10-Q: Q2 2024 Earnings Report
Astrana Health Is Maintained at Buy by Truist Securities
Astrana Health Second Quarter 2024 Earnings: Beats Expectations
Express News | Astrana Health Inc : Truist Securities Raises Target Price to $59 From $50
Truist Securities Raises Price Target on Astrana Health to $59 From $50, Maintains Buy Rating
Bank of America Securities Reaffirms Their Buy Rating on Astrana Health (ASTH)
Astrana Health's Strong Q2 Performance and Strategic Growth Fuel Buy Rating
Does Astrana Health (ASTH) Have a Long Runway for Growth?
Astana Health, Inc. (ASTH) Q2 2024 Earnings Call Transcript
Astrana Health Sees FY24 EPS $1.12-$1.36 Vs $1.42 Est.; Revenue $1.75B-$1.85B Vs $1.76B Est.